Description: Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Home Page: www.amgen.com
One Amgen Center Drive
Thousand Oaks,
CA
91320-1799
United States
Phone:
805 447 1000
Officers
| Name | Title |
|---|---|
| Mr. Robert A. Bradway | Chairman, CEO & President |
| Mr. Peter H. Griffith | Executive VP & CFO |
| Mr. Esteban Santos | Executive Vice President of Operations |
| Dr. David M. Reese M.D. | Executive VP & CTO |
| Mr. Murdo Gordon | Executive Vice President of Global Commercial Operations |
| Mr. Matthew C. Busch | Chief Accounting Officer & VP of Finance |
| Dr. James E. Bradner M.D. | Executive VP of Research & Development and Chief Scientific Officer |
| Mr. Scott Skellenger | Senior VP & Chief Information Officer |
| Justin G. Claeys | Vice President of Investor Relations |
| Mr. Jonathan P. Graham J.D. | Executive VP, General Counsel & Secretary |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 13.245 |
|---|---|
| Trailing PE: | 34.9797 |
| Price-to-Book MRQ: | 19.541 |
| Price-to-Sales TTM: | 4.3117 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 26700 |